Bio-evaluation of doxorubicin (DOX)-incorporated hydroxyapatite (HAp)-chitosan (CS) nanocomposite triggered on osteosarcoma cells

A new strategic nanostructure consisting inorganic-organic combination for cancer dominancy has been successfully developed using doxorubicin (DOX)-assimilated hydroxyapatite (HAp) as filler and chitosan (CS) as matrix by a solution-based chemical method to access a new window in the field of drug delivery systems (DDS). In this research attempt, we have focussed to fetch an anticancer efficacy from a nanoassembly consisting of DOX-coated nanosized HAp and CS. Basically, HAp is a progressive ceramic biomaterial and has been synthesized by a simple in situ precipitation method, in which the reputed anticancer drug DOX was incorporated and the system was further modified by an extensively used polymer CS. CS is an organic polymer that can be obtained from different organic sources, which may provide mechanical strength to the nanocomposite by making interfacial bonding between them. Such a novel nanocomposite has been physicochemically characterized using Fourier transform infrared spectroscopy (FTIR), X-ray diffraction (XRD), transmission electron microscopy (TEM) and particle size distribution (PSD). Also, the in vitro biocompatible assistance of the synthesized HAp and the anticancer activity of the newly derived nanocomposite were evaluated through a colorimetric assay (MTT assay). HAp remains biocompatible to osteosarcoma cells, whereas the DOX-HAp-CS nanocomposite produces a remarkable cytotoxicity towards cultured osteosarcoma cells. The prepared DOX-HAp-CS nanocomposite may be potentially used as an anticancer agent for osteosarcoma inhibition. Doxorubicin (DOX)-intercalated hydroxyapatite (HAp)-chitosan (CS) nanocomposite can be triggered on osteosarcoma cells